The Pulmonary Fibrosis Foundation (PFF) is welcoming applications for its 2023 PFF Scholars program, which helps fund early-stage investigators developing research to improve the outcomes of people with pulmonary fibrosis (PF). Each investigator will receive a two-year research grant totaling $100,000, which is an increase of $25,000 a scholar…
Applications Now Open for 2023 PFF Scholars Program
Navigating the healthcare system on a regular basis can be draining. This is especially true considering that many hospitals, acute care clinics, and family physicians are struggling to deal with a backlog of patients in the wake of the COVID-19 pandemic. Unfortunately, the U.S. Centers for Disease Control and Prevention…
Following the successful completion of preclinical studies, Saniona is now ready to initiate the regulatory process needed to start testing SAN903 — its therapy candidate for idiopathic pulmonary fibrosis (IPF) and other disorders — in Phase 1 human trials. “Preclinical data for SAN903 are very compelling,” Thomas Feldthus,…
Idiopathic pulmonary fibrosis (IPF) patients often require a multidisciplinary team to manage their care. My IPF journey has been shaped by all the medical professionals I’ve encountered along the way. I was formally diagnosed on Jan. 31, 2017, at the Inova Fairfax Hospital’s Advanced Lung Disease and Transplant…
Real-world data support the safety profile of the anti-fibrotic medications Esbriet (pirfenidone) and Ofev (nintedanib) in people with idiopathic pulmonary fibrosis (IPF), according to a new study. More than half of patients experienced treatment-related adverse events, the majority being non-severe gastrointestinal symptoms. Rare cases of serious heart-related…
I have always been passionate about professional development and am often the first to express interest in training sessions, conferences, or webinars to enhance my learning in the field of psychotherapy. Professional development stretches my thinking and introduces concepts I may not have thought about. I recently attended a virtual…
A change in seasons is underway here in Virginia, and across the mid-Atlantic. Trees that were once lush and green are now exploding with fiery red, burnt orange, and golden hues. All of those leaves have also begun to fall from the trees to the ground. Firewood is stacked and…
Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF). The trial is part of the FIBRONEER global program, which also includes FIBRONEER-ILD, a similar Phase…
AbbVie’s portfolio of antibodies for the potential treatment of idiopathic pulmonary fibrosis (IPF) now includes DJS-002 — a first-in-class antibody directed against lysophosphatidic acid receptor-1 (LPAR1), a protein thought to drive the progression of IPF and other fibrotic diseases. This was made possible by AbbVie’s estimated $250 million acquisition of…
When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, it felt like my entire world had shrunk. My wife and caregiver, Susan, and I were suddenly alone on an island. I’m confident many feel this way after receiving a diagnosis. However, a rare, incurable disease can…
